Mode
Text Size
Log in / Sign up

Remote ischemic preconditioning reduces postoperative atrial fibrillation in patients with specific genetic risk factorsTrial Shows Remote Ischemic Preconditioning Reduces Heart Rhythm Issues

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider remote ischemic preconditioning to potentially reduce atrial fibrillation in high-risk genetic populations.

The study evaluated the efficacy of remote ischemic preconditioning (RIPC) in patients possessing a specific loss-of-function genotype undergoing isolated off-pump coronary artery bypass grafting. The primary objective was to determine if RIPC could reduce the incidence of postoperative atrial fibrillation (POAF) within the first week following surgery.

The results indicated that the RIPC group experienced a lower incidence and burden of postoperative atrial fibrillation compared to the control group. Additionally, the intervention was associated with lower levels of platelet aggregation and a reduced inflammatory and prothrombotic index. Patients in the RIPC group also demonstrated a shorter duration of stay in the intensive care unit.

While the study suggests a favorable outcome for RIPC in this specific patient population, the clinical application remains focused on those with the identified genetic markers. The findings suggest that RIPC may mitigate certain physiological stressors during surgery. Clinical adoption should be weighed against the specific patient profile and the need for broader evidence in general surgical populations.

Researchers conducted a randomized controlled trial to see if remote ischemic preconditioning (RIPC) could help patients during heart surgery. The study focused on a specific group of patients who have a certain genetic marker (CYP2C19 loss-of-function) and are undergoing off-pump coronary artery bypass grafting.

The study included 220 patients. One group received the RIPC treatment, which involved three cycles of 5-minute inflation and 5-minute deflation. The other group received no intervention. The results showed that the RIPC group had a much lower rate of atrial fibrillation within the first week of surgery. Specifically, the rate was 24.8% in the RIPC group compared to 41.4% in the control group.

In addition to fewer heart rhythm issues, the RIPC group showed lower levels of inflammation and platelet activity. These patients also spent less time in the intensive care unit. While these results are promising for this specific group of patients, the study is focused on a specific genetic profile. You should talk to your doctor to see if these findings apply to your specific health needs.

What this means for you:
RIPC may reduce heart rhythm issues and inflammation for patients with a specific genetic marker after heart surgery.

Common questions

What is the main benefit of the RIPC treatment?

The study found that the RIPC treatment significantly reduced the occurrence of atrial fibrillation after surgery. In the study, the rate of this heart rhythm issue was 24.8% for those receiving RIPC, compared to 41.4% for those who did not receive it.

Who specifically was included in this study?

This study specifically included 220 patients who had a certain genetic marker (CYP2C19 loss-of-function) and were undergoing a specific type of heart surgery called off-pump coronary artery bypass grafting.

Did the treatment affect recovery time in the hospital?

Yes, the study found that patients who received the RIPC treatment had a significantly shorter stay in the intensive care unit compared to the group that did not receive the intervention.

Study Details

Study typeRct
Sample sizen = 220
EvidenceLevel 2
Follow-up0.2 mo
PublishedOct 2026
View Original Abstract ↓
Off-pump coronary artery bypass grafting (OPCABG) is associated with increased platelet aggregation and a higher incidence of postoperative atrial fibrillation (POAF). Remote ischemic preconditioning (RIPC) has been reported as a promising intervention to mitigate these adverse outcomes. Consecutive patients with cytochrome P450 family 2 subfamily C member 19 (CYP2C19) loss-of-function (LOF) genotype who underwent isolated OPCABG were randomly assigned to receive intermittent ischemia-reperfusion applied to the arm (RIPC group) or not intervention (control group). RIPC was performed after induction of anesthesia using three cycles of 5-min inflation separated by 5-min deflation. The primary outcome was the cumulative incidence of POAF within the first postoperative week, assessed by the intention-to-treat analysis. Secondary outcomes included POAF burden, biochemical indicators, and clinical trajectory. Among the 220 patients available for the primary endpoint analysis, POAF occurred in 27 of 109 patients (24.8%) in the RIPC group versus 46 of 111 patients (41.4%) in the control group (hazard ratio [HR]: 0.542, 95% confidence interval [CI]: 0.342 to 0.858; P = 0.01). The RIPC group also showed significantly lower values than the control group for AF burden (5.1% [IQR 2.3-11.3%] vs. 8.3% [IQR 4.1-19.1%]; P = 0.019), arachidonic acid- and adenosine diphosphate-stimulated platelet aggregation, inflammatory and prothrombotic index, and intensive care unit length of stay. In CYP2C19 LoF carriers, administration of RIPC favorably reduced the incidence and burden of POAF within 1 week after OPCABG, attenuated platelet aggregation and systemic inflammation, and shortened the duration of intensive care unit stay.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.